Base de dados : MEDLINE
Pesquisa : D03.132.327.287.572.522 [Categoria DeCS]
Referências encontradas : 3772 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 378 ir para página                         

  1 / 3772 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457570
[Au] Autor:Ponté C; Lapeyre-Mestre M
[Ad] Endereço:Service de pharmacologie médicale et clinique, Centre d'évaluation et d'information sur la pharmacodépendance-addictovigilance, faculté de médecine, CHU de Toulouse, 37, allées Jules-Guesde, 31000 Toulouse, France. Electronic address: ponte.c@chu-toulouse.fr.
[Ti] Título:[Psychoactive effects of 'legal high': About lysergic acid amide (LSA)].
[Ti] Título:Effets psychoactifs des « legal high ¼ : à propos de l'acide lysergique amide (LSA)..
[So] Source:Therapie;72(5):605-608, 2017 Oct.
[Is] ISSN:0040-5957
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:Lysergic acid amide (LSA) is a natural psychoactive substance consumed as a psychedelic drug. In 2016, 4 cases were reported to the Toulouse Addictovigilance Centre, resulting in unintended psychic effects and led to a hospitalisation in 2 cases. Other cases of serious LSA intoxication are published, including a death. It is important to inform about the risks related to LSA consumption, a substance which is freely available and sometimes hidden behind various plant names.
[Mh] Termos MeSH primário: Alucinógenos/efeitos adversos
Dietilamida do Ácido Lisérgico/análogos & derivados
Transtornos Relacionados ao Uso de Substâncias/complicações
[Mh] Termos MeSH secundário: Adulto
Feminino
França
Seres Humanos
Dietilamida do Ácido Lisérgico/efeitos adversos
Masculino
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hallucinogens); 073830XH10 (lysergamide); 8NA5SWF92O (Lysergic Acid Diethylamide)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171228
[Lr] Data última revisão:
171228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  2 / 3772 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28554863
[Au] Autor:Oellig C
[Ad] Endereço:Institute of Food Chemistry, University of Hohenheim, Garbenstrasse 28, 70599 Stuttgart, Germany. Electronic address: claudia.oellig@uni-hohenheim.de.
[Ti] Título:Lysergic acid amide as chemical marker for the total ergot alkaloids in rye flour - Determination by high-performance thin-layer chromatography-fluorescence detection.
[So] Source:J Chromatogr A;1507:124-131, 2017 Jul 21.
[Is] ISSN:1873-3778
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Ergot alkaloids are generally determined by high-performance liquid chromatography (HPLC) coupled to fluorescence detection (FLD) or mass selective detection, analyzing the individual compounds. However, fast and easy screening methods for the determination of the total ergot alkaloid content are more suitable, since for monitoring only the sum of the alkaloids is relevant. The herein presented screening uses lysergic acid amide (LSA) as chemical marker, formed from ergopeptine alkaloids, and ergometrine for the determination of the total ergot alkaloids in rye with high-performance thin-layer chromatography-fluorescence detection (HPTLC-FLD). An ammonium acetate buffered extraction step was followed by liquid-liquid partition for clean-up before the ergopeptine alkaloids were selectively transformed to LSA and analyzed by HPTLC-FLD on silica gel with isopropyl acetate/methanol/water/25% ammonium hydroxide solution (80:10:3.8:1.1, v/v/v/v) as the mobile phase. The enhanced native fluorescence of LSA and unaffected ergometrine was used for quantitation without any interfering matrix. Limits of detection and quantitation were 8 and 26µg LSA/kg rye, which enables the determination of the total ergot alkaloids far below the applied quality criterion limit for rye. Close to 100% recoveries for different rye flours at relevant spiking levels were obtained. Thus, reliable results were guaranteed, and the fast and efficient screening for the total ergot alkaloids in rye offers a rapid alternative to the HPLC analysis of the individual compounds.
[Mh] Termos MeSH primário: Cromatografia em Camada Delgada/métodos
Alcaloides de Claviceps/análise
Farinha/análise
Dietilamida do Ácido Lisérgico/análogos & derivados
Extratos Vegetais/análise
Secale/química
[Mh] Termos MeSH secundário: Cromatografia em Camada Delgada/instrumentação
Fluorescência
Dietilamida do Ácido Lisérgico/análise
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Ergot Alkaloids); 0 (Plant Extracts); 073830XH10 (lysergamide); 8NA5SWF92O (Lysergic Acid Diethylamide)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170531
[St] Status:MEDLINE


  3 / 3772 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28236857
[Au] Autor:Juszczak GR
[Ad] Endereço:Department of Animal Behavior, Institute of Genetics and Animal Breeding, Polish Academy of Sciences, 05-552 Jastrzebiec, 36a Postepu str., Poland. Electronic address: gjuszczak@yahoo.com.
[Ti] Título:Disrupted integration of sensory stimuli with information about the movement of the body as a mechanism explaining LSD-induced experience.
[So] Source:Med Hypotheses;100:94-97, 2017 Mar.
[Is] ISSN:1532-2777
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:LSD (lysergic acid diethylamide) is a model psychedelic drug used to study mechanism underlying the effects induced by hallucinogens. However, despite advanced knowledge about molecular mechanism responsible for the effects induced by LSD and other related substances acting at serotonergic 5-HT receptors, we still do not understand how these drugs trigger specific sensory experiences. LSD-induced experience is characterised by perception of movement in the environment and by presence of various bodily sensations such as floating in space, merging into surroundings and movement out of the physical body (the out-of-body experience). It means that a large part of the experience induced by the LSD can be simplified to the illusory movement that can be attributed to the self or to external objects. The phenomenology of the LSD-induced experience has been combined with the fact that serotonergic neurons provide all major parts of the brain with information about the level of tonic motor activity, occurrence of external stimuli and the execution of orienting responses. Therefore, it has been proposed that LSD-induced stimulation of 5-HT receptors disrupts the integration of the sensory stimuli with information about the movement of the body leading to perception of illusory movement.
[Mh] Termos MeSH primário: Alucinógenos/farmacologia
Cinestesia/efeitos dos fármacos
Dietilamida do Ácido Lisérgico/farmacologia
[Mh] Termos MeSH secundário: Animais
Encéfalo/efeitos dos fármacos
Encéfalo/metabolismo
Córtex Cerebral/fisiologia
Seres Humanos
Modelos Teóricos
Destreza Motora/efeitos dos fármacos
Movimento
Neurônios/metabolismo
Receptor 5-HT2A de Serotonina/metabolismo
Serotonina/fisiologia
Visão Ocular
Córtex Visual/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hallucinogens); 0 (Receptor, Serotonin, 5-HT2A); 333DO1RDJY (Serotonin); 8NA5SWF92O (Lysergic Acid Diethylamide)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170227
[St] Status:MEDLINE


  4 / 3772 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28129538
[Au] Autor:Wacker D; Wang S; McCorvy JD; Betz RM; Venkatakrishnan AJ; Levit A; Lansu K; Schools ZL; Che T; Nichols DE; Shoichet BK; Dror RO; Roth BL
[Ad] Endereço:Department of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599-7365, USA. Electronic address: dwacker@email.unc.edu.
[Ti] Título:Crystal Structure of an LSD-Bound Human Serotonin Receptor.
[So] Source:Cell;168(3):377-389.e12, 2017 Jan 26.
[Is] ISSN:1097-4172
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The prototypical hallucinogen LSD acts via serotonin receptors, and here we describe the crystal structure of LSD in complex with the human serotonin receptor 5-HT . The complex reveals conformational rearrangements to accommodate LSD, providing a structural explanation for the conformational selectivity of LSD's key diethylamide moiety. LSD dissociates exceptionally slow from both 5-HT R and 5-HT R-a major target for its psychoactivity. Molecular dynamics (MD) simulations suggest that LSD's slow binding kinetics may be due to a "lid" formed by extracellular loop 2 (EL2) at the entrance to the binding pocket. A mutation predicted to increase the mobility of this lid greatly accelerates LSD's binding kinetics and selectively dampens LSD-mediated ß-arrestin2 recruitment. This study thus reveals an unexpected binding mode of LSD; illuminates key features of its kinetics, stereochemistry, and signaling; and provides a molecular explanation for LSD's actions at human serotonin receptors. PAPERCLIP.
[Mh] Termos MeSH primário: Dietilamida do Ácido Lisérgico/química
Receptor 5-HT2B de Serotonina/química
[Mh] Termos MeSH secundário: Arrestina/química
Cristalografia por Raios X
Seres Humanos
Cinética
Modelos Químicos
Simulação de Dinâmica Molecular
[Pt] Tipo de publicação:JOURNAL ARTICLE; COMMENT
[Nm] Nome de substância:
0 (Arrestin); 0 (Receptor, Serotonin, 5-HT2B); 8NA5SWF92O (Lysergic Acid Diethylamide)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171115
[Lr] Data última revisão:
171115
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170128
[St] Status:MEDLINE


  5 / 3772 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28129534
[Au] Autor:Chen Q; Tesmer JJ
[Ad] Endereço:The Life Sciences Institute, University of Michigan, Ann Arbor, MI 48109, USA; Departments of Pharmacology and Biological Chemistry, University of Michigan, Ann Arbor, MI 48109, USA.
[Ti] Título:A Receptor on Acid.
[So] Source:Cell;168(3):339-341, 2017 01 26.
[Is] ISSN:1097-4172
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Wacker et al. report the crystal structure of LSD in complex with one of its major targets in the brain, the 5-HT receptor, the first such structure for any psychedelic drug. The results shed light on the molecular mechanisms underlying its ability to induce hallucinations with greater duration and potency than closely related compounds.
[Mh] Termos MeSH primário: Alucinógenos/farmacologia
Dietilamida do Ácido Lisérgico/análogos & derivados
[Mh] Termos MeSH secundário: Encéfalo/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; COMMENT
[Nm] Nome de substância:
0 (Hallucinogens); 8NA5SWF92O (Lysergic Acid Diethylamide)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170723
[Lr] Data última revisão:
170723
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170128
[St] Status:MEDLINE


  6 / 3772 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28019026
[Au] Autor:Nichols DE; Johnson MW; Nichols CD
[Ad] Endereço:Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
[Ti] Título:Psychedelics as Medicines: An Emerging New Paradigm.
[So] Source:Clin Pharmacol Ther;101(2):209-219, 2017 Feb.
[Is] ISSN:1532-6535
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Scientific interest in serotonergic psychedelics (e.g., psilocybin and LSD; 5-HT receptor agonists) has dramatically increased within the last decade. Clinical studies administering psychedelics with psychotherapy have shown preliminary evidence of robust efficacy in treating anxiety and depression, as well as addiction to tobacco and alcohol. Moreover, recent research has suggested that these compounds have potential efficacy against inflammatory diseases through novel mechanisms, with potential advantages over existing antiinflammatory agents. We propose that psychedelics exert therapeutic effects for psychiatric disorders by acutely destabilizing local brain network hubs and global network connectivity via amplification of neuronal avalanches, providing the occasion for brain network "resetting" after the acute effects have resolved. Antiinflammatory effects may hold promise for efficacy in treatment of inflammation-related nonpsychiatric as well as potentially for psychiatric disorders. Serotonergic psychedelics operate through unique mechanisms that show promising effects for a variety of intractable, debilitating, and lethal disorders, and should be rigorously researched.
[Mh] Termos MeSH primário: Encéfalo/efeitos dos fármacos
Alucinógenos/uso terapêutico
Transtornos Mentais/tratamento farmacológico
[Mh] Termos MeSH secundário: Ansiedade/tratamento farmacológico
Encéfalo/metabolismo
Ensaios Clínicos como Assunto
Depressão/tratamento farmacológico
Relação Dose-Resposta a Droga
Alucinógenos/administração & dosagem
Alucinógenos/efeitos adversos
Alucinógenos/farmacologia
Seres Humanos
Inflamação/tratamento farmacológico
Inflamação/fisiopatologia
Mediadores da Inflamação/metabolismo
Dietilamida do Ácido Lisérgico/uso terapêutico
Terapias Mente-Corpo/métodos
Transtorno Obsessivo-Compulsivo/tratamento farmacológico
Psilocibina/uso terapêutico
Psicoterapia/métodos
Receptor 5-HT2A de Serotonina/biossíntese
Agonistas de Receptores 5-HT2 de Serotonina/farmacologia
Índice de Gravidade de Doença
Transtornos Relacionados ao Uso de Substâncias/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Hallucinogens); 0 (Inflammation Mediators); 0 (Receptor, Serotonin, 5-HT2A); 0 (Serotonin 5-HT2 Receptor Agonists); 2RV7212BP0 (Psilocybin); 8NA5SWF92O (Lysergic Acid Diethylamide)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170529
[Lr] Data última revisão:
170529
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161227
[St] Status:MEDLINE
[do] DOI:10.1002/cpt.557


  7 / 3772 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27305705
[Au] Autor:Gawinecka J; Müller DM; von Eckardstein A; Saleh L
[Ti] Título:Pitfalls of LSD screening assays: comparison of KIMS and CEDIA immunoassays with LC-MS.
[So] Source:Clin Chem Lab Med;55(1):e10-e12, 2017 Jan 01.
[Is] ISSN:1437-4331
[Cp] País de publicação:Germany
[La] Idioma:eng
[Mh] Termos MeSH primário: Imunoensaio
Dietilamida do Ácido Lisérgico/urina
[Mh] Termos MeSH secundário: Cromatografia Líquida
Seres Humanos
Espectrometria de Massas
[Pt] Tipo de publicação:COMPARATIVE STUDY; LETTER
[Nm] Nome de substância:
8NA5SWF92O (Lysergic Acid Diethylamide)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160616
[St] Status:MEDLINE


  8 / 3772 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27265891
[Au] Autor:Brandt SD; Kavanagh PV; Westphal F; Elliott SP; Wallach J; Colestock T; Burrow TE; Chapman SJ; Stratford A; Nichols DE; Halberstadt AL
[Ad] Endereço:School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, UK.
[Ti] Título:Return of the lysergamides. Part II: Analytical and behavioural characterization of N -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ).
[So] Source:Drug Test Anal;9(1):38-50, 2017 Jan.
[Is] ISSN:1942-7611
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Lysergic acid N,N-diethylamide (LSD) is perhaps one of the most intriguing psychoactive substances known and numerous analogs have been explored to varying extents in previous decades. In 2013, N -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ) appeared on the 'research chemicals'/new psychoactive substances (NPS) market in both powdered and blotter form. This study reports the analytical characterization of powdered AL-LAD and LSZ tartrate samples and their semi-quantitative determination on blotter paper. Included in this study was the use of nuclear magnetic resonance (NMR) spectroscopy, gas chromatography-mass spectrometry (GC-MS), low and high mass accuracy electrospray MS(/MS), high performance liquid chromatography diode array detection and GC solid-state infrared analysis. One feature shared by serotonergic psychedelics, such as LSD, is the ability to mediate behavioural responses via activation of 5-HT receptors. Both AL-LAD and LSZ displayed LSD-like responses in male C57BL/6 J mice when employing the head-twitch response (HTR) assay. AL-LAD and LSZ produced nearly identical inverted-U-shaped dose-dependent effects, with the maximal responses occurring at 200 µg/kg. Analysis of the dose responses by nonlinear regression confirmed that LSZ (ED = 114.2 nmol/kg) was equipotent to LSD (ED = 132.8 nmol/kg) in mice, whereas AL-LAD was slightly less potent (ED = 174.9 nmol/kg). The extent to which a comparison in potency can be translated directly to humans requires further investigation. Chemical and pharmacological data obtained from NPS may assist research communities that are interested in various aspects related to substance use and forensic identification. Copyright © 2016 John Wiley & Sons, Ltd.
[Mh] Termos MeSH primário: Dietilamida do Ácido Lisérgico/análogos & derivados
Dietilamida do Ácido Lisérgico/farmacologia
Psicotrópicos/química
Psicotrópicos/farmacologia
Agonistas de Receptores 5-HT2 de Serotonina/química
Agonistas de Receptores 5-HT2 de Serotonina/farmacologia
[Mh] Termos MeSH secundário: Animais
Seres Humanos
Dietilamida do Ácido Lisérgico/administração & dosagem
Masculino
Camundongos Endogâmicos C57BL
Psicotrópicos/administração & dosagem
Receptor 5-HT2A de Serotonina/metabolismo
Agonistas de Receptores 5-HT2 de Serotonina/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Psychotropic Drugs); 0 (Receptor, Serotonin, 5-HT2A); 0 (Serotonin 5-HT2 Receptor Agonists); 8NA5SWF92O (Lysergic Acid Diethylamide)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170516
[Lr] Data última revisão:
170516
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160607
[St] Status:MEDLINE
[do] DOI:10.1002/dta.1985


  9 / 3772 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27886063
[Au] Autor:De Gregorio D; Comai S; Posa L; Gobbi G
[Ad] Endereço:Neurobiological Psychiatry Unit, McGill University, Montreal, QC H3A 1A1, Canada. danilo.degregorio@mail.mcgill.ca.
[Ti] Título:d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.
[So] Source:Int J Mol Sci;17(11), 2016 Nov 23.
[Is] ISSN:1422-0067
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:d-Lysergic Acid Diethylamide (LSD) is known for its hallucinogenic properties and psychotic-like symptoms, especially at high doses. It is indeed used as a pharmacological model of psychosis in preclinical research. The goal of this review was to understand the mechanism of action of psychotic-like effects of LSD. We searched Pubmed, Web of Science, Scopus, Google Scholar and articles' reference lists for preclinical studies regarding the mechanism of action involved in the psychotic-like effects induced by LSD. LSD's mechanism of action is pleiotropic, primarily mediated by the serotonergic system in the Dorsal Raphe, binding the 5-HT receptor as a partial agonist and 5-HT as an agonist. LSD also modulates the Ventral Tegmental Area, at higher doses, by stimulating dopamine D2, Trace Amine Associate receptor 1 (TAAR1) and 5-HT . More studies clarifying the mechanism of action of the psychotic-like symptoms or psychosis induced by LSD in humans are needed. LSD's effects are mediated by a pleiotropic mechanism involving serotonergic, dopaminergic, and glutamatergic neurotransmission. Thus, the LSD-induced psychosis is a useful model to test the therapeutic efficacy of potential novel antipsychotic drugs, particularly drugs with dual serotonergic and dopaminergic (DA) mechanism or acting on TAAR1 receptors.
[Mh] Termos MeSH primário: Núcleo Dorsal da Rafe/metabolismo
Alucinógenos/farmacologia
Dietilamida do Ácido Lisérgico/farmacologia
Transtornos Psicóticos/metabolismo
Agonistas de Receptores de Serotonina/farmacologia
Área Tegmentar Ventral/metabolismo
[Mh] Termos MeSH secundário: Animais
Antipsicóticos/farmacologia
Comportamento Animal/efeitos dos fármacos
Modelos Animais de Doenças
Dopamina/metabolismo
Dopamina/farmacologia
Núcleo Dorsal da Rafe/efeitos dos fármacos
Núcleo Dorsal da Rafe/fisiopatologia
Avaliação Pré-Clínica de Medicamentos
Alucinógenos/metabolismo
Seres Humanos
Dietilamida do Ácido Lisérgico/metabolismo
Transtornos Psicóticos/tratamento farmacológico
Transtornos Psicóticos/fisiopatologia
Ratos
Receptor 5-HT1A de Serotonina/metabolismo
Receptor 5-HT2A de Serotonina/metabolismo
Receptores Dopaminérgicos/metabolismo
Receptores Acoplados a Proteínas-G/metabolismo
Receptores de Glutamato/metabolismo
Agonistas de Receptores de Serotonina/metabolismo
Transmissão Sináptica/efeitos dos fármacos
Área Tegmentar Ventral/efeitos dos fármacos
Área Tegmentar Ventral/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Hallucinogens); 0 (Receptor, Serotonin, 5-HT2A); 0 (Receptors, Dopamine); 0 (Receptors, G-Protein-Coupled); 0 (Receptors, Glutamate); 0 (Serotonin Receptor Agonists); 0 (Trace amine-associated receptor 1); 112692-38-3 (Receptor, Serotonin, 5-HT1A); 8NA5SWF92O (Lysergic Acid Diethylamide); VTD58H1Z2X (Dopamine)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170330
[Lr] Data última revisão:
170330
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161126
[St] Status:MEDLINE


  10 / 3772 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27501227
[Au] Autor:Holloway T; Moreno JL; González-Maeso J
[Ad] Endereço:Department of Psychiatry, Icahn School of Medicine at Mount Sinai.
[Ti] Título:HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice.
[So] Source:J Vis Exp;(113), 2016 Jul 09.
[Is] ISSN:1940-087X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The heteromeric receptor complex between 5-HT2A and mGlu2 has been implicated in some of the behavioral phenotypes in mouse models of psychosis(1,2). Consequently, investigation of structural details of the interaction between 5-HT2A and mGlu2 affecting schizophrenia-related behaviors represents a powerful translational tool. As previously shown, the head-twitch response (HTR) in mice is elicited by hallucinogenic drugs and this behavioral response is absent in 5-HT2A knockout (KO) mice(3,4). Additionally, by conditionally expressing the 5-HT2A receptor only in cortex, it was demonstrated that 5-HT2A receptor-dependent signaling pathways on cortical pyramidal neurons are sufficient to elicit head-twitch behavior in response to hallucinogenic drugs(3). Finally, it has been shown that the head-twitch behavioral response induced by the hallucinogens DOI and lysergic acid diethylamide (LSD) is significantly decreased in mGlu2-KO mice(5). These findings suggest that mGlu2 is at least in part necessary for the 5-HT2A receptor-dependent psychosis-like behavioral effects induced by LSD-like drugs. However, this does not provide evidence as to whether the 5-HT2A-mGlu2 receptor complex is necessary for this behavioral phenotype. To address this question, herpes simplex virus (HSV) constructs to express either mGlu2 or mGlu2ΔTM4N (mGlu2/mGlu3 chimeric construct that does not form the 5-HT2A-mGlu2 receptor complex) in the frontal cortex of mGlu2-KO mice were used to examine whether this GPCR heteromeric complex is needed for the behavioral effects induced by LSD-like drugs(6).
[Mh] Termos MeSH primário: Simplexvirus
[Mh] Termos MeSH secundário: Animais
Alucinógenos
Dietilamida do Ácido Lisérgico
Camundongos
Camundongos Knockout
Receptor 5-HT2A de Serotonina
Transgenes
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hallucinogens); 0 (Receptor, Serotonin, 5-HT2A); 8NA5SWF92O (Lysergic Acid Diethylamide)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170811
[Lr] Data última revisão:
170811
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160809
[St] Status:MEDLINE
[do] DOI:10.3791/53717



página 1 de 378 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde